For related articles and more information, please visit OCA’s Health Issues page and our Appetite For a Change page.

There are currently two HPV vaccines on the market, but if there was any regard for sound scientific evidence, neither would be promoted as heavily as they are.

 The first, Gardasil, was licensed by the US Food and Drug Administration (FDA) in 2006. It is now recommended as a routine vaccination for girls and women between the ages of 9-26 in the US. On October 25, 2011, the CDC’s Advisory Committee on Immunization Practices also voted to recommend giving the HPV vaccine to males between the ages of 11 and 21. The second HPV vaccine, Cervarix, was licensed in 2009.

 Were it to be discovered that the HPV vaccine, in fact, does not effectively prevent cancer, then young women (and now boys) are being exposed to clearly unacceptable health risks. And that’s precisely what a recent study has concluded…

Review of HPV Trials Conclude Effectiveness is Still Completely Unproven

 Published online on September 24,1 a systematic review of pre- and post-licensure trials of the HPV vaccine by a Canadian team shows that its effectiveness is not only overstated (through the use of selective reporting or “cherry picking” data) but also completely
unproven.